New Cholesterol-Lowering drug HRS-1301 enters Mid-Stage trial
NCT ID NCT07229937
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests an experimental drug called HRS-1301 in people with high cholesterol (dyslipidemia). About 189 participants will receive one of four doses of HRS-1301 or a placebo daily for 12 weeks. The main goal is to see how much the drug lowers 'bad' LDL cholesterol and to find the best dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HRS-1301 (an experimental oral drug to lower cholesterol)
What this could lead to
If successful, this could provide a new treatment option for managing high cholesterol and reducing heart disease risk.
What could go wrong
This is an early Phase 2 trial with only 189 participants, so results may not apply to everyone. The drug may not work better than existing treatments or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERLIPIDEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The 2nd Affiliated Hospital of Harbin
RECRUITINGHarbin, Heilongjiang, 150086, China
Contact